Paul Workman, president and CEO of The Institute of Cancer Research, recently accepted an appointment to the STORM Therapeutics board of directors.
"I am delighted to be joining the board of STORM and working with the company in this exploding area of biology,” Workman said in a press release. “RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. I look forward to working with the board to help guide STORM's innovative research programs, adding my experience from drug discovery in academia, pharma and biotech."
STORM Therapeutics selected Workman to join its board as an independent director to continue its goal of becoming the premier therapeutics company in RNA epigenetic modulation and its growth in a managerial and advisory capacity, according to the release.
“Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies,” STORM CEO Keith Blundy said in the release.
STORM Therapeutics is affiliated with the University of Cambridge in the United Kingdom. It focuses on furthering pioneering work in the field of RNA epigenetics to develop drugs to combat cancer and other diseases, according to the release.